 Arrowhead Pharmaceuticals Inc NASDAQ: ARWR has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma ccRCC. ARO-HIF2 is the first tumor-targeted investigational medicine to utilizing Arrowheads Targeted RNAi Molecule TRiM platform. 